FDA Crackdown On Unapproved Drugs Has Incentives For Voluntary Submissions

FDA is encouraging manufacturers of marketed but unapproved drugs to voluntarily submit applications by highlighting the possibility of a de facto exclusivity period for sponsors who receive NDA approval for a drug that other firms are marketing without approval